BioSpace News Archive

Kenox Pharmaceuticals Inc has submitted Type B Pre-Investigational New Drug (IND) meeting request with the U.S. Food and Drug Administration (FDA) for its lead program KNX018.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global hysteroscopy systems market is expected to grow at a 5% CAGR during the forecast period between 2019 to 2029, predicts Fact.MR.

Pixium Vision SA announces that it will attend the 11th Annual LifeSci Partners Corporate Access Event, being held virtually from January 5 to 7, 2022.

ERYTECH Pharma announced that it has entered into a definitive agreement with Armistice, ahealth-care focused institutional and accredited investor, for the purchase and sale of 769,608units, each Unit consisting of four ordinary shares in the form of American Depositary Shares and three warrants, each to purchase one ordinary share, in a registered direct offering to specified categories of investors, described below.

A clinical trial is a process carried out to ascertain the effectiveness and safety of a pharmaceutical preparation.

Fact.MR – A Market Research and Competitive Intelligence Provider: As per latest Fact.MR analysis, the dental lasers market is anticipated to accelerate at a healthy CAGR of around 9% through 2022.

Anastrozole is an oral non-selective aromatase inhibitor approved for adjuvant treatment of early-stage, hormone receptor-positive breast cancer in postmenopausal women.

Cellworks Group, Inc., today announced the results from two clinical studies using the Cellworks Biosimulation Platform and Computational Omics Biology Model (CBM) to predict therapy response for individual MDS patients were featured in two poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition held December 11-14, 2021 in Atlanta, Georgia.

Chinook Therapeutics, Inc. today announced the European Commission has granted orphan drug designation for atrasentan for the treatment of primary IgA nephropathy (IgAN).

sterna biologicals GmbH & Co. KG, a clinical-stage immunology company developing novel biological treatments for chronic inflammatory diseases, announced that the first patient has been dosed in the Company’s phase IIa proof-of-concept trial with SB010 in patients with moderate to severe Type-2 driven asthma.